hrp0095p2-132 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Hyperinsulinaemic Hypoglycaemia – are neonates symptomatic during hypoglycaemia?

Cousins Ruth , Athanasakopoulou Sapfo , Urs Mithuna , Shah Pratik

Introduction: Over recent years, hyperinsulinaemic hypoglycaemia is being increasingly recognised in at-risk neonates; it is important to recognise and manage this promptly in view of the risk of hypoglycaemic brain injury.Aims: To recognise signs and symptoms of hypoglycaemia in neonates with hyperinsulinaemic hypoglycaemia.Methods: Neonates from the neonatal intensive care units ...

hrp0095p1-96 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Optimizing Diazoxide dose for the treatment of newborns with hyperinsulinemic hypoglycaemia (HH)

Neha Malhotra , Buddhi Gunasekara , Sapfo Athanasakopoulou , Clare Gilbert , Kate Morgan , Mehul Dattani , Antonia Dastamani

Introduction: Early initiation of diazoxide (DZX) treatment in neonates with HH can prevent permanent hypoglycaemic brain injury. The DZX standard therapeutic dose (STD) is 5 mg/kg/day, and rarely associated with adverse events. There are limited data for the effectiveness and safety of DZX low-dose (<5mg/kg/day) for the treatment of HH neonates.Aim: To assess efficacy and safety of low-dose DZX in HH newborns.<p ...